BRIGHTEN: A Game-based Neurodevelopmental Assessment for Young Children

Sponsor
Brightlobe Limited (Industry)
Overall Status
Recruiting
CT.gov ID
NCT05780853
Collaborator
(none)
590
1
17
34.7

Study Details

Study Description

Brief Summary

The aim of this study is to evaluate a novel tablet game-based neurodevelopmental assessment tool for young children aged 3 to 8 years old.

The study's main aims are: (1) to determine whether the novel tablet-game based assessment tool can accurately differentiate children's neurodevelopmental status based on their performance on the game and (2) assess the validity of the game-based neurodevelopment assessment tool.

The study aims to recruit 590 children who are 'typically' developing and/or have a diagnosed neurodevelopmental disorder including Attention Deficit Hyperactivity Disorder (ADHD), Autism Spectrum Disorder (ASD), Specific Learning Disorder, or a Communication Disorder.

All participants will complete the tablet game-based assessment which aims to assess a range of neuropsychological functions including attention, memory, language, motor, executive functions and social-emotional skills. Parents/carers of participants will also complete a demographic questionnaire and the Adaptive Behaviour System - Third Edition (ABAS-3), which is a questionnaire that assesses a child's development. Some participants will be re-tested on the tablet game-based assessment approximately 2 weeks after the first tablet game-based assessment to ensure the game's validity.

Condition or Disease Intervention/Treatment Phase
  • Diagnostic Test: Tablet Game-based Assessment
  • Diagnostic Test: Adaptive Behavior Assessment System, Third Edition (ABAS-3)
  • Other: Demographic questionnaire

Study Design

Study Type:
Observational
Anticipated Enrollment :
590 participants
Observational Model:
Case-Control
Time Perspective:
Prospective
Official Title:
Evaluation of a Novel Game-based Neurodevelopmental Assessment for Young Children
Actual Study Start Date :
Jan 30, 2023
Anticipated Primary Completion Date :
Dec 1, 2023
Anticipated Study Completion Date :
Jun 30, 2024

Arms and Interventions

Arm Intervention/Treatment
Typically Developing Children (Control Group)

Typically developing children with no known neurodevelopmental disorder, medical comorbidities, a chronic illness or any additional diagnoses that would impact their ability to complete the game-based assessment.

Diagnostic Test: Tablet Game-based Assessment
Tablet game-based assessment to assess neurodevelopmental profile.

Diagnostic Test: Adaptive Behavior Assessment System, Third Edition (ABAS-3)
A parent-reported child behavioural assessment questionnaire used to diagnose and classify various developmental, learning and behavioural disabilities and disorders.

Other: Demographic questionnaire
Parent/carer and child's demographic data such as age, ethnicity, employment status, household income, medical history and education status.

Children with a Diagnosed Neurodevelopmental Disorder (Clinical Group)

Children with a diagnosed neurodevelopmental disorder including: Attention Deficit Hyperactivity Disorder (ADHD), Autism Spectrum Disorder (ASD), Specific Learning Disorder, or a Communication Disorder. Children must also have no known medical comorbidities, a chronic illness or any additional diagnoses that would impact their ability to complete the game-based assessment.

Diagnostic Test: Tablet Game-based Assessment
Tablet game-based assessment to assess neurodevelopmental profile.

Diagnostic Test: Adaptive Behavior Assessment System, Third Edition (ABAS-3)
A parent-reported child behavioural assessment questionnaire used to diagnose and classify various developmental, learning and behavioural disabilities and disorders.

Other: Demographic questionnaire
Parent/carer and child's demographic data such as age, ethnicity, employment status, household income, medical history and education status.

Outcome Measures

Primary Outcome Measures

  1. Diagnostic accuracy of the tablet game-based assessment [16 months]

    Sensitivity and specificity of the tablet game-based assessment to accurately differentiate children's neurodevelopmental status.

  2. Construct validity of the tablet game-based assessment [16 months]

    Using exploratory factor analysis to explore the construct validity of the tablet game-based assessment.

  3. Internal consistency of the tablet game-based assessment [16 months]

    Cronbach's alpha and omega statistic to assess internal consistency/reliability of the tool, which assesses the extent to which all the items in the game-based assessment measure the same concept or construct.

  4. Known-group and predictive validity of the tablet game-based assessment [16 months]

    Known-group and predictive validity will both be assessed through multiple logistic regression.

Secondary Outcome Measures

  1. Preliminary normative data for performance on the tablet game-based assessment tool [16 months]

    Performance on the tablet game-based assessment tool will be obtained from metadata and psychometric data obtained from the game-based assessment tool and device such as response time, correct/incorrect responses and gyroscope readings. Performance scores may be dichotomous, continuous and/or counts. Preliminary normative data for performance on the tablet game-based assessment tool will be defined through an exploratory factor analysis.

  2. Acceptability of the tablet game-based assessment tool and device [16 months]

    Parent and child acceptability of the tablet-game based assessment tool and device will be conducted by asking parents 3 brief questions to assess parental perception of acceptability (e.g. Having seen your child complete the game today, how do you think they found the experience?). Child acceptability will be accessed using a smileyometer scale (5 ratings) to rate how they felt about the game-based assessment. Children will also be asked 8 brief questions about their opinions on the game (e.g. What did you think about the game?).

  3. Re-test reliability of the tablet game-based assessment tool [16 months]

    Acceptable levels of test-retest reliability/stability using Intraclass Correlation Coefficient (ICC) at two different time points within 2 weeks.

  4. Safety of the tablet game-based assessment tool and device [16 months]

    Any adverse events occurring during the duration of the study will be recorded and reported at the end of the study. These will be recorded as the number of events with qualitative data about the nature of the event. These events will then be grouped into different types of risk, and how likely they would be to occur in any future use of the device.

Other Outcome Measures

  1. Participant demographics [16 momths]

    Descriptive analyses of participant demographics (e.g., age, ethnicity, employment status, household income, medical history and education status)

  2. Scores on the Adaptive Behavior Assessment System, Third Edition (ABAS-3) [16 months]

    Scores on the parent-reported questionnaire (ABAS-3)

Eligibility Criteria

Criteria

Ages Eligible for Study:
3 Years to 8 Years
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
Yes
Inclusion Criteria:
  • 3 to 8 year old 'typically' developing children with no known neurodevelopmental disorder.

OR

  • 3 to 8 year old children with a diagnosed neurodevelopmental disorder, including Attention Deficit Hyperactivity Disorder (ADHD), Autism Spectrum Disorder (ASD), Specific Learning Disorder, or a Communication Disorder.

All parents/caregivers and children must have a minimum level of English fluency required to complete the parent questionnaire and the game-based assessment.

Exclusion Criteria:
  • Children with medical comorbidities, a chronic illness or any additional diagnoses that would impact their ability to complete the game-based assessment.

Contacts and Locations

Locations

Site City State Country Postal Code
1 Brightlobe Limited London United Kingdom

Sponsors and Collaborators

  • Brightlobe Limited

Investigators

  • Principal Investigator: Jane Iles, PhD DClinPsy, Brightlobe Limited

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Brightlobe Limited
ClinicalTrials.gov Identifier:
NCT05780853
Other Study ID Numbers:
  • BRIGHTEN-01
First Posted:
Mar 23, 2023
Last Update Posted:
Mar 23, 2023
Last Verified:
Mar 1, 2023
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Keywords provided by Brightlobe Limited
Additional relevant MeSH terms:

Study Results

No Results Posted as of Mar 23, 2023